Traditional Three-incision Esophagectomy Versus Minimally Invasive Thorascopic and Laparoscopic Esophagectomy

NCT02448966 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 1000

Last updated 2015-05-20

No results posted yet for this study

Summary

Esophageal carcinoma is an aggressive malignancy with poor prognosis. Surgical resection remains the most effective method for this malignant disease. VATS esophagectomy has become more and more popular in China and around the world. Although VATS esophagectomy has been proven to be effective in preventing respiratory complications, there is still no ample evidences to demonstrate that VATS esophagectomy is as effective as traditional three-incision esophagectomy in lymph node dissection and is equal or superior in long-term survival. The purpose of this large scale prospective observational study is to compare the minimally invasive thorascopic/laparoscopic esophagectomy with traditional three-incision esophagectomy in lymph node dissection, postoperative recovery, postoperative complications, and long-term survival.

Conditions

  • Esophageal Cancer

Interventions

PROCEDURE

open esophagectomy

PROCEDURE

Minimally invasive esophagectomy

Sponsors & Collaborators

  • Peking University Cancer Hospital & Institute

    collaborator OTHER
  • Henan Cancer Hospital

    collaborator OTHER_GOV
  • Hebei Medical University Fourth Hospital

    collaborator OTHER
  • Shanghai Zhongshan Hospital

    collaborator OTHER
  • Harbin Medical University

    collaborator OTHER
  • Sichuan Cancer Hospital and Research Institute

    collaborator OTHER
  • Fujian Cancer Hospital

    collaborator OTHER_GOV
  • Liaoning Cancer Hospital & Institute

    collaborator OTHER
  • Hunan Cancer Hospital

    collaborator OTHER
  • Sun Yat-sen University

    collaborator OTHER
  • Zhejiang Cancer Hospital

    collaborator OTHER
  • Tang-Du Hospital

    collaborator OTHER
  • Shanghai Chest Hospital

    collaborator OTHER
  • Chinese Academy of Medical Sciences

    lead OTHER

Principal Investigators

  • Jie He, MD,PhD · Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-01-31
Primary Completion
2017-12-31
Completion
2019-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02448966 on ClinicalTrials.gov